Merit Medical Systems Q3 2026 earnings
Merit delivered 9% organic constant currency revenue growth and raised full-year guidance.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $416.2M | +8.4% | -0.5% | Ex. 99.1, income statement |
| EPS (GAAP) | $0.70 | +50.0% | +7.7% | Ex. 99.1, income statement |
| EPS (adjusted) | $1.12 | +21.7% | +5.9% | Ex. 99.1, income statement |
| Net income | $42.3M | +52.4% | +9.6% | Ex. 99.1, income statement |
| Adj. EBITDA | $67.4M | +22.7% | +6.2% | Ex. 99.1, income statement |
| Adj. EBITDA margin | 16.2% | +1.5 pp | +0.5 pp | Ex. 99.1, income statement |
Revenue breakdown
not stated in the 8-K
Margins and costs
- Gross margin 48.2% (52.8% non-GAAP)
- Operating expenses $141.9M (+1.3% YoY)
- One-offs in the quarter Contingent consideration benefit $0.04M; Corporate restructuring $0.03M; Acquisition-related $0.03M; Medical Device Regulation expenses $0.01M
- Effective tax rate 24.2% (24.1% YoY)
- Non-GAAP bridge Adds back amortization of intangibles, performance-based share-based compensation, corporate restructuring, acquisition-related expenses, and Medical Device Regulation expenses.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Cash and cash equivalents | $503.6M | $448.7M | $446.4M | +12.3% |
| Total debt obligations | $747.5M | $747.5M | $747.5M | 0% |
| Available borrowing capacity | $697M | $697M | $697M | 0% |
Guidance
| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| Total Revenue | $1.635 - $1.642B | $1.631 - $1.643B | Narrowed |
| Non-GAAP Earnings Per Share | $4.33 - $4.37 | $4.25 - $4.35 | Raised |
What drove it
- Revenue story Revenue grew 8.4% year-over-year, driven by 9% organic constant currency growth, excluding a strategic divestiture.
- EPS story EPS growth was driven by higher revenue and improved non-GAAP operating margins.
- One-off check Contingent consideration benefit of $0.04M (pre-tax) in Q3 2026.
The good
- 9% organic constant currency revenue growth
- Non-GAAP operating margin increased 17% YoY
- Non-GAAP EPS increased 22% YoY
The bad
- GAAP gross margin decreased 0.3 pp YoY to 48.2%
- Revenue declined 0.5% sequentially
The ugly
- none
Open questions
- The release does not disclose revenue by segment or region.
- The release does not provide a reconciliation of GAAP to non-GAAP measures.
Full release
Earnings: MMSI — filed 2026-10-29
FOR IMMEDIATE RELEASE
MERIT MEDICAL REPORTS THIRD QUARTER 2026 RESULTS: DELIVERS 9% ORGANIC CONSTANT CURRENCY REVENUE GROWTH AND RAISES FULL-YEAR 2026 GUIDANCE
Financial Highlights†
† Comparisons above are calculated for the current quarter compared with the third quarter of 2025, unless otherwise specified. Amounts stated in this release are rounded, while percentages are calculated from the underlying amounts.
* Constant currency revenue; constant currency revenue, organic; non-GAAP gross profit and margin; non-GAAP operating income and margin; non-GAAP net income; non-GAAP EPS; and free cash flow figures (used here and below) are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading “Non-GAAP Financial Measures” below.
SOUTH JORDAN, Utah, October 29, 2026 -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced financial results for the three and nine-month periods ended September 30, 2026.
“Merit delivered third quarter financial results that exceeded the high end of our expectations, driven primarily by 9% organic, constant currency revenue growth, excluding the impact of a strategic divestiture,” said Martha G. Aronson, Merit’s President and CEO. “We experienced strong revenue growth trends in the U.S. and better-than-expected demand for Merit’s products across both our Foundational and our Therapeutic platforms. We also delivered strong growth in both our non-GAAP operating profit and our non-GAAP earnings per share, which increased 17% and 22%, respectively, year-over-year.” Ms. Aronson¹ continued: “We have raised our 2026 revenue and non-GAAP earnings per share guidance to reflect the stronger-than-expected results over the first nine months of 2026 and remain confident in our team’s ability to execute, with attractive constant currency growth, improving profitability, and solid cash flow generation this year. Our team remains focused on delivering our Continued Growth Initiative financial targets for the three-year period ending December 31, 2026, and, in parallel, we are finalizing our longer-term strategic plan focused on identifying opportunities to better position the company for sustainable growth, enhanced profitability and value creation for our shareholders.”
Merit’s revenue by product category for the three and nine-month periods ended September 30, 2026 and 2025 was as follows (unaudited; in thousands, except for percentages):
²
Financial Summary:
GAAP gross margin was 48.2%, compared to 48.5% for the third quarter of 2025. Non-GAAP gross margin* was 52.8%, compared to 53.6% for the third quarter of 2025.
GAAP operating margin was 14.1%, compared to 11.1% for the third quarter of 2025. Non-GAAP operating margin* was 21.3%, compared to 19.7% for the third quarter of 2025.
GAAP net income was $42.3 million, or $0.70 per share, compared to $27.8 million, or $0.46 per share, for the third quarter of 2025. Non-GAAP net income* was $67.4 million, or $1.12 per share, compared to $54.9 million, or $0.92 per share, for the third quarter of 2025.
As of September 30, 2026, Merit had cash and cash equivalents of $503.6 million and total debt obligations of $747.5 million, compared to cash and cash equivalents of $446.4 million and total debt obligations of $747.5 million as of December 31, 2025. Merit had available borrowing capacity of approximately $697 million as of September 30, 2026.
Fiscal Year 2026 Financial Guidance
Based upon the information currently available to Merit’s management, for the twelve-month period ending December 31, 2026, absent the potential impact of trade policies and related actions implemented by the U.S. and other countries subsequent to today’s date, material acquisitions, non-recurring transactions or other factors beyond Merit’s current expectations, Merit anticipates the following financial results:
Revenue and Earnings Guidance*
*Percentage figures approximated; dollar figures may not foot due to rounding.
Financial statements
Income Statement
Revenue and Earnings Guidance*
| Updated Guidance – Year Ending – December 31, 2026 | Updated Guidance – % Change – Y/Y | Prior Guidance(2) – Year Ending – December 31, 2026 | Prior Guidance(2) – % Change – Y/Y | |
|---|---|---|---|---|
| Total Revenue | $1.635 - $1.642 billion | 8% - 8% | $1.631 - $1.643 billion | 8% - 8% |
| Non-GAAP Earnings Per Share(1) | $4.33 - $4.37 | 13% - 14% | $4.25 - $4.35 | 11% - 14% |
Income Statement
Three Months Ended — (Unaudited, in thousands except per share amounts)
| Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | Nine Months Ended – September 30, – 2026 | Nine Months Ended – September 30, – 2025 | |
|---|---|---|---|---|
| Net sales | 416,244 | 384,157 | 1,216,964 | 1,121,970 |
| Cost of sales | 215,613 | 197,746 | 616,370 | 579,052 |
| Gross profit | 200,631 | 186,411 | 600,594 | 542,918 |
| Operating expenses: | ||||
| Selling, general and administrative | 119,511 | 119,801 | 366,950 | 340,384 |
| Research and development | 22,393 | 23,966 | 70,391 | 70,811 |
| Contingent consideration (benefit) expense | -36 | 32 | -70 | 1,198 |
| Total operating expenses | 141,868 | 143,799 | 437,271 | 412,393 |
| Income from operations | 58,763 | 42,612 | 163,323 | 130,525 |
| Other income (expense): | ||||
| Interest income | 4,128 | 3,615 | 11,780 | 11,166 |
| Interest expense | -7,333 | -6,754 | -25,977 | -20,097 |
| Other income (expense) — net | 227 | -933 | 11,519 | -1,717 |
| Total other expense — net | -2,978 | -4,072 | -2,678 | -10,648 |
| Income before income taxes | 55,785 | 38,540 | 160,645 | 119,877 |
| Income tax expense | 13,474 | 10,785 | 38,536 | 29,394 |
| Net income | 42,311 | 27,755 | 122,109 | 90,483 |
| Earnings per common share | ||||
| Basic | 0.71 | 0.47 | 2.05 | 1.53 |
| Diluted | 0.7 | 0.46 | 2.03 | 1.49 |
| Weighted average shares outstanding | ||||
| Basic | 59,806 | 59,245 | 59,666 | 59,095 |
| Diluted | 60,379 | 59,919 | 60,134 | 60,604 |
Income Statement
Three Months Ended — (Unaudited, in thousands except per share amounts)
| Three Months Ended – September 30, 2026 – Pre-Tax | Three Months Ended – September 30, 2026 – Tax Impact | Three Months Ended – September 30, 2026 – After-Tax | Three Months Ended – September 30, 2026 – Per Share Impact | |
|---|---|---|---|---|
| GAAP net income | 55,785 | -13,474 | 42,311 | 0.7 |
| Cost of Sales | ||||
| Amortization of intangibles | 18,996 | -4,484 | 14,512 | 0.24 |
| Operating Expenses | ||||
| Contingent consideration benefit | -36 | -14 | -50 | 0 |
| Amortization of intangibles | 2,540 | -600 | 1,940 | 0.03 |
| Performance-based share-based compensation (a) | 7,173 | -665 | 6,508 | 0.11 |
| Corporate restructuring (b) | 301 | -71 | 230 | 0 |
| Acquisition-related | 280 | -11 | 269 | 0 |
| Medical Device Regulation expenses (c) | 519 | -123 | 396 | 0.01 |
| Other (Income) Expense | ||||
| Long-term debt costs (e) | 1,414 | -334 | 1,080 | 0.02 |
| Other non-operating loss (f) | 254 | -60 | 194 | 0 |
| Non-GAAP net income | 87,226 | -19,836 | 67,390 | 1.12 |
| Diluted shares | 60,379 | |||
Income Statement
Three Months Ended — (Unaudited, in thousands except per share amounts)
| Three Months Ended – September 30, 2025 – Pre-Tax | Three Months Ended – September 30, 2025 – Tax Impact | Three Months Ended – September 30, 2025 – After-Tax | Three Months Ended – September 30, 2025 – Per Share Impact | |
|---|---|---|---|---|
| GAAP net income | 38,540 | -10,785 | 27,755 | 0.46 |
| Cost of Sales | ||||
| Amortization of intangibles | 19,212 | -4,539 | 14,673 | 0.24 |
| Inventory mark-up related to acquisitions | 183 | -43 | 140 | 0 |
| Operating Expenses | ||||
| Contingent consideration expense | 32 | -5 | 27 | 0 |
| Amortization of intangibles | 2,560 | -604 | 1,956 | 0.03 |
| Performance-based share-based compensation (a) | 9,028 | -1,413 | 7,615 | 0.13 |
| Corporate restructuring (b) | 286 | -67 | 219 | 0 |
| Acquisition-related | -68 | 16 | -52 | 0 |
| Medical Device Regulation expenses (c) | 1,655 | -391 | 1,264 | 0.02 |
| Other (d) | 74 | -17 | 57 | 0 |
| Other (Income) Expense | ||||
| Long-term debt costs (e) | 1,414 | -334 | 1,080 | 0.02 |
| Other non-operating loss (f) | 260 | -61 | 199 | 0 |
| Non-GAAP net income | 73,176 | -18,243 | 54,933 | 0.92 |
| Diluted shares | 59,919 | |||
Income Statement
Nine Months Ended — (Unaudited, in thousands except per share amounts)
| Nine Months Ended – September 30, 2026 – Pre-Tax | Nine Months Ended – September 30, 2026 – Tax Impact | Nine Months Ended – September 30, 2026 – After-Tax | Nine Months Ended – September 30, 2026 – Per Share Impact | |
|---|---|---|---|---|
| GAAP net income | 160,645 | -38,536 | 122,109 | 2.03 |
| Cost of Sales | ||||
| Amortization of intangibles | 55,941 | -13,206 | 42,735 | 0.71 |
| Operating Expenses | ||||
| Contingent consideration benefit | -70 | -9 | -79 | 0 |
| Amortization of intangibles | 7,490 | -1,768 | 5,722 | 0.1 |
| Performance-based share-based compensation (a) | 19,602 | -1,727 | 17,875 | 0.3 |
| Corporate restructuring (b) | 2,460 | -581 | 1,879 | 0.03 |
| Acquisition-related | 7,091 | -916 | 6,175 | 0.1 |
| Medical Device Regulation expenses (c) | 2,589 | -611 | 1,978 | 0.03 |
| Other (Income) Expense | ||||
| Long-term debt costs (e) | 9,305 | -2,197 | 7,108 | 0.12 |
| Gain on disposal of business unit | -12,502 | 1,520 | -10,982 | -0.18 |
| Other non-operating loss (f) | 1,079 | -267 | 812 | 0.01 |
Income Statement
Nine Months Ended — (Unaudited, in thousands except per share amounts)
| Nine Months Ended – September 30, 2025 – Pre-Tax | Nine Months Ended – September 30, 2025 – Tax Impact | Nine Months Ended – September 30, 2025 – After-Tax | Nine Months Ended – September 30, 2025 – Per Share Impact | |
|---|---|---|---|---|
| GAAP net income | 119,877 | -29,394 | 90,483 | 1.49 |
| Cost of Sales | ||||
| Amortization of intangibles | 55,798 | -13,184 | 42,614 | 0.7 |
| Inventory mark-up related to acquisitions | 250 | -59 | 191 | 0 |
| Operating Expenses | ||||
| Contingent consideration expense | 1,198 | 29 | 1,227 | 0.02 |
| Amortization of intangibles | 7,497 | -1,771 | 5,726 | 0.09 |
| Performance-based share-based compensation (a) | 19,681 | -2,344 | 17,337 | 0.29 |
| Corporate restructuring (b) | 2,873 | -678 | 2,195 | 0.04 |
| Acquisition-related | 2,088 | -2 | 2,086 | 0.03 |
| Medical Device Regulation expenses (c) | 4,883 | -1,153 | 3,730 | 0.06 |
| Other (d) | 103 | -24 | 79 | 0 |
| Other (Income) Expense | ||||
| Long-term debt costs (e) | 4,242 | -1,002 | 3,240 | 0.05 |
| Other non-operating loss (f) | 11 | -61 | -50 | 0 |
| Non-GAAP net income | 218,501 | -49,643 | 168,858 | 2.79 |
| Diluted shares | 60,604 | |||
Income Statement
Three Months Ended — (Unaudited, in thousands except percentages)
| Three Months Ended – September 30, 2026 – Amounts | Three Months Ended – September 30, 2026 – % Sales | Three Months Ended – September 30, 2025 – Amounts | Three Months Ended – September 30, 2025 – % Sales | Nine Months Ended – September 30, 2026 – Amounts | Nine Months Ended – September 30, 2026 – % Sales | Nine Months Ended – September 30, 2025 – Amounts | Nine Months Ended – September 30, 2025 – % Sales | |
|---|---|---|---|---|---|---|---|---|
| Net Sales as Reported | 416,244 | 384,157 | 1,216,964 | 1,121,970 | ||||
| GAAP Operating Income | 58,763 | 14.1% | 42,612 | 11.1% | 163,323 | 13.4% | 130,525 | 11.6% |
| Cost of Sales | ||||||||
| Amortization of intangibles | 18,996 | 4.6% | 19,212 | 5.0% | 55,941 | 4.6% | 55,798 | 5.0% |
| Inventory mark-up related to acquisitions | 183 | 0.0% | 250 | 0.0% | ||||
| Operating Expenses | ||||||||
| Contingent consideration (benefit) expense | -36 | -0.0% | 32 | 0.0% | -70 | -0.0% | 1,198 | 0.1% |
| Amortization of intangibles | 2,540 | 0.6% | 2,560 | 0.7% | 7,490 | 0.6% | 7,497 | 0.7% |
| Performance-based share-based compensation (a) | 7,173 | 1.7% | 9,028 | 2.4% | 19,602 | 1.6% | 19,681 | 1.8% |
| Corporate restructuring (b) | 301 | 0.1% | 286 | 0.1% | 2,460 | 0.2% | 2,873 | 0.3% |
| Acquisition-related | 280 | 0.1% | -68 | -0.0% | 7,091 | 0.6% | 2,088 | 0.2% |
| Medical Device Regulation expenses (c) | 519 | 0.1% | 1,655 | 0.4% | 2,589 | 0.2% | 4,883 | 0.4% |
| Other (d) | 74 | 0.0% | 103 | 0.0% | ||||
| Non-GAAP Operating Income | 88,536 | 21.3% | 75,574 | 19.7% | 258,426 | 21.2% | 224,896 | 20.0% |
Balance Sheet
September 30, — (in thousands)
| September 30, – 2026 | December 31, – 2025 | |
|---|---|---|
| fp | ||
| ASSETS | (Unaudited) | |
| Current Assets | ||
| Cash and cash equivalents | 503,551 | 446,404 |
| Trade receivables, net | 221,866 | 203,710 |
| Other receivables | 37,875 | 17,773 |
| Inventories | 391,022 | 333,705 |
| Prepaid expenses and other current assets | 35,188 | 31,493 |
| Prepaid income taxes | 5,030 | 4,941 |
| Income tax refund receivables | 4,283 | 2,128 |
| Total current assets | 1,198,815 | 1,040,154 |
| Property and equipment, net | 437,347 | 428,401 |
| Intangible assets, net | 591,204 | 537,654 |
| Goodwill | 537,135 | 506,837 |
| Deferred income tax assets | 7,273 | 7,049 |
| Right-of-use operating lease assets | 84,379 | 87,600 |
| Other assets | 68,753 | 78,227 |
| Total Assets | 2,924,906 | 2,685,922 |
| Current Liabilities | ||
| Trade payables | 66,286 | 60,551 |
| Accrued expenses | 174,024 | 159,486 |
| Short-term operating lease liabilities | 10,382 | 10,876 |
| Income taxes payable | 14,391 | 8,851 |
| Total current liabilities | 265,083 | 239,764 |
| Long-term debt | 737,404 | 734,038 |
| Deferred income tax liabilities | 37,216 | 19,665 |
| Liabilities related to unrecognized tax benefits | 2,248 | 2,248 |
| Deferred compensation payable | 19,373 | 17,542 |
| Deferred credits | 1,321 | 1,398 |
| Long-term operating lease liabilities | 74,273 | 76,658 |
| Other long-term obligations | 43,437 | 10,306 |
| Total liabilities | 1,180,355 | 1,101,619 |
| Stockholders' Equity | ||
| Common stock | 808,930 | 763,909 |
| Retained earnings | 946,139 | 824,030 |
| Accumulated other comprehensive loss | -10,518 | -3,636 |
| Total stockholders' equity | 1,744,551 | 1,584,303 |
| Total Liabilities and Stockholders' Equity | 2,924,906 | 2,685,922 |
Cash Flow
Nine Months Ended — (Unaudited, in thousands)
| Nine Months Ended – September 30, – 2026 | Nine Months Ended – September 30, – 2025 | |
|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net income | 122,109 | 90,483 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 93,383 | 91,629 |
| Gain on disposition of a business | -12,557 | -249 |
(1) Merit’s non-GAAP earnings per share reflect the dilutive impact of its 3.00% Convertible Senior Notes due 2029 (the “Convertible Notes”) calculated using the if-converted method of approximately $0.01 per share for the year ending December 31, 2026. Any offsetting impacts of the capped call associated with the Convertible Notes are not considered.
(2) “Prior Guidance” reflects Merit’s full-year 2026 financial guidance, previously introduced on July 30, 2026.
Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of various items which could impact Merit’s future financial results, such as expenses attributable to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain employee termination benefits, performance-based stock compensation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reasonably predict the amount and impact of these items and Merit believes inclusion of the most comparable GAAP financial measure, and a reconciliation of these forward-looking non-GAAP measures to their GAAP counterparts could be confusing to investors or cause undue reliance.
Merit’s financial guidance for the year ending December 31, 2026 is subject to risks and uncertainties identified in this release and Merit’s filings with the SEC. This guidance is based on information and estimates available to Merit as of October 29, 2026. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results will likely vary, and could vary materially, from past results and those anticipated, estimated or projected.³
CONFERENCE CALL
As previously announced, Merit will hold its investor conference call today, Thursday, October 29, 2026, at 4:30 p.m., Eastern Time, to discuss its results for the third quarter and provide an operational update.
To access the conference call, please pre-register using the following link.
Registrants will receive confirmation with dial-in details.
A live webcast and slide deck will also be available at merit.com.